ARS Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression. We show 12 historical shares outstanding datapoints in our SPRY shares outstanding history coverage, used to compute SPRY market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SPRY market cap history over the course of time is important for investors
interested in comparing SPRY's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SPRY versus a peer is one thing; comparing
SPRY market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SPRY can fluctuate over the course of history.
With this page we aim to empower investors researching SPRY by allowing them to research the SPRY market cap history. |
Free SPRY Email Alerts:
Video: The Importance of Market Cap
